OTLC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OTLC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Preferred stock is a special equity security that has properties of both equity and debt. Oncotelic Therapeutics's preferred stock for the quarter that ended in Dec. 2023 was $0.00 Mil.
The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Oncotelic Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $27.15 Mil.
In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Oncotelic Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.03.
Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Oncotelic Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.00.
The historical data trend for Oncotelic Therapeutics's Preferred Stock can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncotelic Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Preferred Stock | Get a 7-Day Free Trial | - | - | - | - | - |
Oncotelic Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Preferred Stock | Get a 7-Day Free Trial | - | - | - | - | - |
Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.
Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.
Preferred stock comes in many forms. It can be:
A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.
Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?
It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.
Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.
Oncotelic Therapeutics (OTCPK:OTLC) Preferred Stock Explanation
When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.
For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffetts Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffetts Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?
1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.
Oncotelic Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value | |||||||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation | + | Minority Interest |
= | 15.268788 | + | 0 | + | 1.898 | + | 10.675 | + | -0.519 |
- | Cash, Cash Equivalents, Marketable Securities | ||||||||
- | 0.17 | ||||||||
= | 27.15 |
2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.
Oncotelic Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is calculated as
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (Diluted Average) |
= | (12.13 | - | 0) | / | 399.184 | |
= | 0.03 |
3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.
Oncotelic Therapeutics's Earnings per Share (Diluted) (EPS) for the three months ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-0.736 | - | 0) | / | 398.949 | |
= | -0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Oncotelic Therapeutics's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.
Vuong Trieu | officer: CHIEF EXECUTIVE OFFICER | 4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301 |
Saran Saund | officer: CHIEF BUSINESS OFFICER | C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301 |
Amit B. Shah | officer: CHIEF FINANCIAL OFFICER | 10 AGUILA, ALISO VIEJO CA 92656 |
Chulho Park | officer: CHIEF TECHNOLOGY OFFICER | 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Maida Anthony E Iii | director | 157 TECHNOLOGY DR, IRVINE CA 92618 |
Steven W King | director | |
David Diamond | director | 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301 |
Fatih Uckun | 10 percent owner, officer: Chief Medical Officer | 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Chao Hsiao | 10 percent owner | 701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080 |
Larn Hwang | 10 percent owner | C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748 |
Donald Rogers Reynolds | director | C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607 |
Sandage Bobby W Phd | director | C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173 |
Simon Pedder | director | 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203 |
Matthew M Loar | officer: Chief Financial Officer | 505 PENOBSCOT DR, REDWOOD CITY CA 94063 |
Pamela Ha | officer: Controller | 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Value_Insider Value_Insider • 11-08-2022
By sperokesalga sperokesalga • 03-20-2023
By Marketwired • 08-25-2023
By sperokesalga sperokesalga • 04-24-2023
By sperokesalga sperokesalga • 06-12-2023
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By Stock market mentor Stock market mentor • 02-06-2023
By GuruFocusNews GuruFocusNews • 07-04-2022
By Marketwired • 08-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.